In a study of elderly, predominately male veterans, statin use was associated with a 36 percent reduction in risk of fracture when compared with no lipid-lowering therapy.

Several biological mechanisms have been proposed to explain an association between statins and bone health, including reduced inflammation and promotion of new bone growth through improvements in small blood vessel function.

Previous studies have shown an association between statin use and fracture reduction. However, most studies have been of populations of women even though many statin users are elderly men with heart disease. The authors suggest that assessing this relationship in a male population would be especially relevant.

Richard E. Scranton, of the Massachusetts Veterans Epidemiology Research and Information Center, Boston, and colleagues analyzed data from patients who received care in the V.A. health care system between January 1, 1998, and June 30, 2001 to compare the rate of bone fractures in individuals using statins versus those not taking statins.

Of the 91,052 individuals included in the study, 28,063 were prescribed only statins, 2,195 were prescribed nonstatin lipid-lowering medications alone, and the remaining 60,794 were not prescribed any lipid-lowering medications during the period of the study.

" More than 28,000 of these individuals were using statins, making this study one of the largest to evaluate the association between statins and fractures," the researchers report. " The use of statins in this study was associated with a 36 percent reduction in fracture risk compared with no lipid-lowering therapy and a 32 percent risk reduction when compared with other lipid-lowering therapy. These findings did not deviate significantly after adjustment for various covariates, including BMI."

" In our large cohort of mostly male veterans, statin therapy was associated with a reduction in fractures," the authors conclude. Our study represents one of the largest studies to date of individuals receiving statins and the evaluation of fracture risk.”

Source: American Medical Association, 2005


XagenaMedicine2005